← Research library

Phenoxyacetamide structural analogues of Chlodantane and ADK-918

Patent disclosure · 2018

What the patent describes
Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.
Reported evidence
The patent explicitly identifies its two adamantane-containing phenoxyacetamides as structural analogues of ADK-910 and ADK-918. This documents a later medicinal-chemistry branch, not demonstrated clinical superiority.

Analogue 1 recovery · 15.1 g, 85% yield · Manufacturing result for the newly claimed analogue, not Chlodantane or ADK-918

Reported patent results

Reported findings

The disclosure reports synthesis yields; it does not supply a verified clinical adaptogenic result.

Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.

Population or model Chemical preparation and characterization of two new phenoxyacetamide analogues, with the original ADK compounds used as structural context.

Results · Final two chemical examples and characterization results.
MeasureResultComparison, timing and statistics
Analogue 1 recovery15.1 g, 85% yieldManufacturing result for the newly claimed analogue, not Chlodantane or ADK-918
Analogue 2 recovery80% yield; melting interval 94.5–95.0°CA different new analogue; analytical characterization

Chemical yields do not establish biological adaptogenic activity. The claimed compounds are structural analogues of the reference candidates, not the candidates themselves.

Source for these results ↗ · Reviewed 2026-11-06

Patent claims and provenance

Platform context. The claimed phenoxyacetamides are described as structural analogues of ADK-910 and ADK-918, rather than claims to those reference compounds themselves.

A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.

Publication
RU2660654C1 ↗ · 2018-07-09
Earliest priority / filing
2017-06-09 / 2017-06-09
Original applicant / assignee
Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный технический университет" (ВолгГТУ)
Indexed status
Not shown; official status unverified · checked 2026-11-06
Patent family
62815866 · family publications are related filings, not independent studies.
Original title, inventors and related publications

N-(adamantan-2-yl)- and n-[(adamantan-1-yl)methyl]- derivatives of 2-(4-allyl-2-methoxyphenoxy)acetic acid amide, which are potential synthetic adaptogens of emergency action

Inventors: Иван Александрович Новаков; Лейла Липпаритовна Брунилина; Андрей Александрович Вернигора; Максим Борисович Навроцкий; Борис Семёнович Орлинсон; Александр Сергеевич Яблоков.

RU2660654C1

Original patent PDF ↗

Patent collection and status interpretation →

Study limitations and source details

Study limitations

  • Chemistry and preclinical observations do not establish human efficacy or safety.

Source details

Source identity and selected abstract or text passages checked; complete methods not appraised.

Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.

Sources checked

Citation

Patent / reported experimentsFull text available

Author unconfirmed. Phenoxyacetamide structural analogues of Chlodantane and ADK-918 RU2660654C1; Volgograd State Technical University

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards